Literature DB >> 24642643

Optimizing treatment benefit: individualized therapy or the polypill?

Jasper J Brugts1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24642643     DOI： 10.1038/nrcardio.2013.185-c1

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  6 in total

1.  Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.

Authors:  Jasper Jan Brugts; Aaron Isaacs; Eric Boersma; Cock M van Duijn; Andre G Uitterlinden; Willem Remme; Michel Bertrand; Toshiharu Ninomiya; Claudio Ceconi; John Chalmers; Stephen MacMahon; Kim Fox; Roberto Ferrari; Jacqueline C M Witteman; A H Jan Danser; Maarten L Simoons; Moniek P M de Maat
Journal:  Eur Heart J       Date:  2010-06-10       Impact factor: 29.983

2.  Prevention: coronary artery calcium and polypill therapy.

Authors:  Ruth Webster; Anthony Rodgers
Journal:  Nat Rev Cardiol       Date:  2013-11-26       Impact factor: 32.419

3.  Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease.

Authors:  Haiyan Wu; Anton J M Roks; Frank P J Leijten; Ingrid M Garrelds; Usha M Musterd-Bhaggoe; Antoon J van den Bogaerdt; Moniek P M de Maat; Maarten L Simoons; A H Jan Danser; Hisko Oeseburg
Journal:  Clin Sci (Lond)       Date:  2014-03       Impact factor: 6.124

4.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

5.  The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.

Authors:  Jasper J Brugts; Toshiharu Ninomiya; Eric Boersma; Willem J Remme; Michel Bertrand; Roberto Ferrari; Kim Fox; Stephen MacMahon; John Chalmers; Maarten L Simoons
Journal:  Eur Heart J       Date:  2009-04-04       Impact factor: 29.983

6.  Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Márcio Sommer Bittencourt; Michael J Blaha; Ron Blankstein; Matthew Budoff; Jose D Vargas; Roger S Blumenthal; Arthur S Agatston; Khurram Nasir
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094
  6 in total
  1 in total

1.  Reply: Personalization of therapy and polypills.

Authors:  Ruth Webster; Anthony Rodgers
Journal:  Nat Rev Cardiol       Date:  2014-03-18       Impact factor: 32.419
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.